A Research Base in Karolinska to Develop Medicine for Alzheimer' s Disease
On June 19, Sumitomo Pharmaceuticals concluded a 5-year-contract with Sweden' s Karolinska Institutet for collaborative research in the development of medicine to treat Alzheimer' s disease. The institute, a medical university and research center in Sweden, is globally known for its achievements in life sciences. It evaluates and selects Nobel Prize recipients for physiology and medicine. Its Alzheimer' s Disease Research Centre in particular has led the world' s research into the disease both quantitatively as well as qualitatively.
Our company will establish research facilities within the Karolinska Alzheimer' s Disease Research Centre. In close cooperation with the center, we shall carry out basic research to elucidate the mechanism for the disease' s pathogenesis and develop efficacious medicine on the basis of the study results, taking advantage of its excellent brain bank and abundant expertise. We shall bear the expenses for maintaining the facilities and conducting research. All results obtained through our research belong to Sumitomo Pharmaceuticals, which has exclusive rights to the manufacturing of any promising compound and the marketing of it throughout the world.
Our company has focused its research efforts on psychoneural disorders. Our endeavor has made commercially available Dops, an anti-parkinsonism agent, and Sediel, anxiolytic; Lullan and SM-13496 to treat schizophrenia and other forms of psychopathy and BDNF (brain-derived neurotrophic factor) are also under research and development.
The incidence of Alzheimer' s disease is expected to rise throughout the world. Its etymology remains unknown and its pharmacological cure out of reach. That is why the disease is being treated as a primary target of our research.
Collaboration with overseas research institutions is an effective means to obtain promising medicinal materials and state-of-the-art data, Sumitomo Pharmaceuticals has chosen as its best collaborator the Karolinska Institutet, which is in the vanguard of the study of Alzheimer' s disease.
In negotiating and concluding this contract, we are greatly indebted to the support and cooperation of the Swedish government and Swedish Embassy in Japan. Our joint research will accelerate the steps towards the medicinal treatment of Alzheimer' s disease and improve our R&D ability in the field of psychoneural disorders.